Repeated talaporfin sodium photodynamic therapy for esophageal cancer: safety and efficacy

Esophagus. 2021 Oct;18(4):817-824. doi: 10.1007/s10388-021-00853-x. Epub 2021 Jun 9.

Abstract

Background: Talaporfin sodium photodynamic therapy (tPDT) is an effective salvage treatment for local failure after chemoradiotherapy for esophageal cancer. Repeated tPDT could also be indicated for local recurrence or residue after the first salvage tPDT. However, the safety and efficacy of repeated tPDT have not been elucidated.

Methods: We reviewed 52 patients with esophageal cancer who were treated with the first tPDT at Kyoto University Hospital between October 2015 and April 2020.

Results: Among 52 patients, repeated tPDT after the first tPDT was indicated for 13 patients (25%), of which six had residual tumor, four had local recurrence after complete response (CR) after the first tPDT at the primary site, and six had metachronous lesion. The total session of repeated tPDT was 25; 16 were for primary sites and nine were for metachronous sites. Among them, six patients (46.2%) achieved local (L)-CR and nine lesions (56.3%) achieved lesion L-CR. By session, 10 sessions (40%) achieved L-CR. There were no severe adverse events except for one patient; this patient showed grade 3 esophageal stenosis and perforation after the third tPDT on the same lesion that was previously treated with porfimer sodium photodynamic therapy four times.

Conclusion: Repeated tPDT could be an effective and safe treatment for local failure even after salvage tPDT for esophageal cancer.

Keywords: Esophageal cancer; Photodynamic therapy; Salvage treatment.

MeSH terms

  • Carcinoma, Squamous Cell* / pathology
  • Esophageal Neoplasms* / pathology
  • Humans
  • Neoplasm Recurrence, Local / pathology
  • Photochemotherapy* / adverse effects
  • Porphyrins

Substances

  • Porphyrins
  • Talaporfin